At a glance
- Originator Abbott Laboratories
- Class Antiallergics; Antirheumatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Rheumatic disorders
Most Recent Events
- 31 Jan 2013 Discontinued for Asthma in USA (PO)
- 31 Jan 2013 Discontinued for Rheumatic disorders in USA (PO)
- 02 Nov 1995 No-Development-Reported for Asthma in USA (PO)